AI News
10 Oct 2026
Read 8 min
How Aiforia PathAI integration expands lab access
Aiforia PathAI integration embeds CE‑IVD AI into AISight Dx, widening lab access across US, Europe.
The Aiforia PathAI integration brings CE-IVD digital pathology AI to more labs by embedding Aiforia’s models into PathAI’s AISight Dx platform. Labs in the US and Europe gain a single workflow for image review, biomarker quantification, and decision support, with unified contracting, billing, and IT connectivity.
PathAI, part of the Roche Group, will offer Aiforia’s deep learning models through the AISight Marketplace. This move links Aiforia’s CE-IVD applications in Europe with PathAI’s large US footprint. Together, they aim to speed adoption of AI in clinical pathology and make advanced tools easier to access and support.
Unified workflow: Case review and AI live in one screen, which can reduce turnaround time and errors.
Broader access: Sites in the US and Europe can reach models through the AISight Marketplace.
Managed adoption: Contracting, billing, and support run through PathAI for simpler onboarding.
Scalable toolkit: Labs can add models from a curated catalog as needs grow.
IT efficiency: AISight Link supports connectivity to existing lab and hospital systems.
Focused insights: Tools aim to support biomarker quantification, tissue classification, and diagnostic decision support.
AISight Dx carries CE-IVD marking for primary diagnosis in the EEA, Switzerland, and the UK.
Aiforia’s CE-IVD applications are available in Europe and will be accessible through AISight Dx.
PathAI’s installed base in the US provides a ready channel to expand access, with usage aligned to local regulations and lab policies.
Less toggling: AI results appear in the same place as the slide and case data.
Consistent experience: One interface, one login, and one process for multiple models.
Actionable outputs: Quantitative readouts can support consistent reporting across teams.
Team alignment: Shared tools help standardize workflows across multi-site networks.
Assess current digital pathology setup and storage needs.
Plan interfaces with LIS and EMR through AISight Link.
Pilot with a defined set of cases and one or two priority models.
Define use policies that reflect regulatory status in your region.
Set review protocols for AI outputs and human oversight.
Monitor performance with routine QA and drift checks.
Provide short, role-based training for pathologists and technologists.
Use sample cases to build comfort with AI overlays and metrics.
Document best practices for when and how to apply each model.
Why It Matters for Clinical Labs
Clinical labs face rising case volumes and staffing pressure. Many also juggle multiple software tools that do not talk to each other. This partnership focuses on one platform for case review and AI. It can cut clicks, lower IT burden, and reduce the time to get value from digital pathology.How the Aiforia PathAI integration Works
Inside AISight Dx
The Aiforia PathAI integration embeds Aiforia’s image analysis models directly into AISight Dx, PathAI’s image management system. AISight Dx is CE-IVD marked for primary diagnosis in the EEA, Switzerland, and the UK. Pathologists can launch AI within the same case review screen, which keeps focus on the slide and the report.Connectivity with AISight Link
AISight Link connects the platform with lab and hospital systems. It supports data flow to LIS and other IT tools, which helps reduce manual steps. With this setup, labs can review slides, run models, and move outputs into reports without jumping between apps.What the Partnership Delivers
Aiforia brings a portfolio of digital pathology applications in Europe. PathAI brings platform reach in the US, a growing algorithm catalog, and a commercial and support model that many labs already use. The result is access to AI across more sites with one vendor relationship.Benefits You Can Expect
Regulatory and Market Footprint
What It Means for Pathologists
Operational Considerations
Implementation
Governance
Training
Looking Ahead
As more validated models arrive, a shared platform can speed safe adoption. A curated marketplace also helps labs avoid fragmented purchases. The Aiforia PathAI integration could further support multi-site standardization and help align research, validation, and clinical use on one system. This partnership signals a practical path to scale pathology AI. By meeting labs where they work today, it reduces adoption friction. With unified workflows, regulatory footing in Europe, and strong US reach, the Aiforia PathAI integration gives labs a clearer route to bring AI into daily practice and measure impact.For more news: Click Here
FAQ
Q: What is the Aiforia PathAI integration?
A: The Aiforia PathAI integration embeds Aiforia’s CE-IVD digital pathology AI models directly into PathAI’s AISight Dx image management platform to broaden access across the US and Europe. It creates a single workflow for case review, biomarker quantification, and diagnostic decision support with contracting, billing, and support managed through PathAI.
Q: Which laboratories and regions can access the integrated AI tools?
A: Clinical laboratories in Europe and the United States can access Aiforia’s models through the AISight Marketplace, leveraging PathAI’s installed base in the US and Aiforia’s CE-IVD applications in Europe. AISight Dx carries CE-IVD marking for primary diagnosis in the EEA, Switzerland, and the UK, and usage should follow local regulations and lab policies.
Q: How does the Aiforia PathAI integration change pathologist workflows?
A: The Aiforia PathAI integration embeds image analysis tools directly into the AISight Dx case review screen so pathologists can run AI without switching applications, keeping focus on the slide and the report. This reduces clicks and IT burden while supporting biomarker quantification and diagnostic decision support.
Q: How does the integration connect with laboratory information systems and hospital IT?
A: The Aiforia PathAI integration uses AISight Link to connect AISight Dx with LIS and other hospital IT systems, enabling data flow from AI outputs into reports and reducing manual steps. This connectivity helps labs review slides, run models, and move results into the LIS or EMR without jumping between apps.
Q: What regulatory considerations should laboratories keep in mind with this partnership?
A: Labs should note that AISight Dx holds CE-IVD marking for primary diagnosis in the EEA, Switzerland, and the UK and that Aiforia’s CE-IVD applications are available in Europe. Use of models will need to align with regional regulations and each lab’s governance and policies.
Q: What operational benefits can laboratories expect from the Aiforia PathAI integration?
A: Through the Aiforia PathAI integration, labs can expect a unified case review and AI workflow that can reduce turnaround time and errors, broader access via the AISight Marketplace, and managed contracting, billing, and support through PathAI. The partnership also offers a scalable, curated algorithm catalog and IT efficiency via AISight Link connectivity.
Q: How should a lab approach implementation and governance when adopting these AI tools?
A: Implementation planning should assess current digital pathology setup and storage, plan interfaces with LIS and EMR via AISight Link, and pilot with a defined set of cases and priority models. Governance should define regional use policies, set review protocols for AI outputs, and include routine QA and model drift monitoring.
Q: How will day-to-day work change for pathologists using the integrated platform?
A: Pathologists will see AI results and quantitative readouts within the same case review screen, which reduces toggling, provides a consistent interface and supports standardized reporting across teams. That shared workflow can help align practices across multi-site networks and make AI outputs more actionable in routine diagnosis.
Contents
